Exact Mass: 361.1823882
Exact Mass Matches: 361.1823882
Found 500 metabolites which its exact mass value is equals to given mass value 361.1823882,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Ofloxacin
C18H20FN3O4 (361.14377720000005)
Ofloxacin is only found in individuals that have used or taken this drug. It is a synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem]Ofloxacin acts on DNA gyrase and toposiomerase IV, enzymes which, like human topoisomerase, prevents the excessive supercoiling of DNA during replication or transcription. By inhibiting their function, the drug thereby inhibits normal cell division. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065609 - Cytochrome P-450 CYP1A2 Inhibitors D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AE - Fluoroquinolones D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones S - Sensory organs > S02 - Otologicals > S02A - Antiinfectives > S02AA - Antiinfectives C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic CONFIDENCE standard compound; EAWAG_UCHEM_ID 3073 CONFIDENCE standard compound; INTERNAL_ID 4075 CONFIDENCE standard compound; INTERNAL_ID 1033
Levofloxacin
C18H20FN3O4 (361.14377720000005)
Levofloxacin is a synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. Levofloxacin is marketed by Ortho-McNeil under the trade name Levaquin. Chemically, levofloxacin is the S-enantiomer (L-isomer) of ofloxacin. -- Wikipedia [HMDB] Levofloxacin is a synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. Levofloxacin is marketed by Ortho-McNeil under the trade name Levaquin. Chemically, levofloxacin is the S-enantiomer (L-isomer) of ofloxacin. -- Wikipedia. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065609 - Cytochrome P-450 CYP1A2 Inhibitors D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AE - Fluoroquinolones D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Methyloctatropine bromide
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
Ethacridine lactate Monohydrate
C18H23N3O5 (361.16376280000003)
D000890 - Anti-Infective Agents
4-Hydroxydecanedioylcarnitine
C17H31NO7 (361.21004159999995)
4-Hydroxydecanedioylcarnitine is an acylcarnitine. More specifically, it is an 4-hydroxydecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hydroxydecanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Hydroxydecanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Hydroxydecanedioylcarnitine
C17H31NO7 (361.21004159999995)
3-Hydroxydecanedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxydecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydecanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydecanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
5-Hydroxydecanedioylcarnitine
C17H31NO7 (361.21004159999995)
5-Hydroxydecanedioylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxydecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydecanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydecanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Carbocromen
C20H27NO5 (361.18891320000006)
C - Cardiovascular system > C01 - Cardiac therapy > C01D - Vasodilators used in cardiac diseases C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
Octocrylene
C1892 - Chemopreventive Agent > C851 - Sunscreen
rac S 33138
Semagacestat
N-(4-(4-Amino-2-ethyl-imidazo(4,5-c)quinolin-1-yl)butyl)methanesulfonamide
C308 - Immunotherapeutic Agent > C2139 - Immunostimulant > C177174 - Toll-like Receptor Agonist
Levofloxacin
C18H20FN3O4 (361.14377720000005)
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065609 - Cytochrome P-450 CYP1A2 Inhibitors D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AE - Fluoroquinolones D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic CONFIDENCE standard compound; EAWAG_UCHEM_ID 3239 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Methylevoxine
Origin: Plant; SubCategory_DNP: Alkaloids derived from anthranilic acid, Quinoline alkaloids
ofloxacin
C18H20FN3O4 (361.14377720000005)
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065609 - Cytochrome P-450 CYP1A2 Inhibitors D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AE - Fluoroquinolones D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones S - Sensory organs > S02 - Otologicals > S02A - Antiinfectives > S02AA - Antiinfectives C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic CASMI2013 Challenge_16 MS2 data, retention time = 3.7 min CASMI2013 Challenge_16 MS1 data, retention time = 3.7 min
Octocrylene
C1892 - Chemopreventive Agent > C851 - Sunscreen CONFIDENCE standard compound; INTERNAL_ID 2501 CONFIDENCE standard compound; INTERNAL_ID 8141 CONFIDENCE standard compound; EAWAG_UCHEM_ID 229
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentan-1-yl)-1H-indole-3-carboxamide
1alphaH,5alphaH,6betaH,7alphaH,11betaH-3beta-hydroxy-11alpha-[(tetrahydro-5-oxo-furan-2-yl)methylamino]methylguaia-4(15),10(14)-dien-12,6-olide|scorzoaustriacin
C20H27NO5 (361.18891320000006)
2alpha-methoxy-6-O-methyllycorenine
C20H27NO5 (361.18891320000006)
Levofloxacin
C18H20FN3O4 (361.14377720000005)
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065609 - Cytochrome P-450 CYP1A2 Inhibitors D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AE - Fluoroquinolones D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Ala Ala Asn Ser
Ala Ala Ser Asn
Ala Gly Lys Ser
Ala Gly Asn Thr
Ala Gly Gln Ser
Ala Gly Ser Lys
Ala Gly Ser Gln
Ala Gly Thr Asn
Ala Lys Gly Ser
Ala Lys Ser Gly
Ala Asn Ala Ser
Ala Asn Gly Thr
Ala Asn Ser Ala
Ala Asn Thr Gly
Ala Gln Gly Ser
Ala Gln Ser Gly
Ala Ser Ala Asn
Ala Ser Gly Lys
Ala Ser Gly Gln
Ala Ser Lys Gly
Ala Ser Asn Ala
Ala Ser Gln Gly
Ala Thr Gly Asn
Ala Thr Asn Gly
Gly Ala Lys Ser
Gly Ala Asn Thr
Gly Ala Gln Ser
Gly Ala Ser Lys
Gly Ala Ser Gln
Gly Ala Thr Asn
Gly Gly Lys Thr
Gly Gly Gln Thr
Gly Gly Thr Lys
Gly Gly Thr Gln
Gly Lys Ala Ser
Gly Lys Gly Thr
Gly Lys Ser Ala
Gly Lys Thr Gly
Gly Asn Ala Thr
Gly Asn Thr Ala
Gly Gln Ala Ser
Gly Gln Gly Thr
Gly Gln Ser Ala
Gly Gln Thr Gly
Gly Ser Ala Lys
Gly Ser Ala Gln
Gly Ser Lys Ala
Gly Ser Gln Ala
Gly Thr Ala Asn
Gly Thr Gly Lys
Gly Thr Gly Gln
Gly Thr Lys Gly
Gly Thr Asn Ala
Gly Thr Gln Gly
N-Acetylnorfloxacin
C18H20FN3O4 (361.14377720000005)
Lys Ala Gly Ser
Lys Ala Ser Gly
Lys Gly Ala Ser
Lys Gly Gly Thr
Lys Gly Ser Ala
Lys Gly Thr Gly
Lys Ser Ala Gly
Lys Ser Gly Ala
Lys Thr Gly Gly
Asn Ala Ala Ser
Asn Ala Gly Thr
Asn Ala Ser Ala
Asn Ala Thr Gly
Asn Gly Ala Thr
Asn Gly Thr Ala
Asn Ser Ala Ala
Asn Thr Ala Gly
Asn Thr Gly Ala
Gln Ala Gly Ser
Gln Ala Ser Gly
Gln Gly Ala Ser
Gln Gly Gly Thr
Gln Gly Ser Ala
Gln Gly Thr Gly
Gln Ser Ala Gly
Gln Ser Gly Ala
Gln Thr Gly Gly
Ser Ala Ala Asn
Ser Ala Gly Lys
Ser Ala Gly Gln
Ser Ala Lys Gly
Ser Ala Asn Ala
Ser Ala Gln Gly
Ser Gly Ala Lys
Ser Gly Ala Gln
Ser Gly Lys Ala
Ser Gly Gln Ala
Ser Lys Ala Gly
Ser Lys Gly Ala
Ser Asn Ala Ala
Ser Gln Ala Gly
Ser Gln Gly Ala
Thr Ala Gly Asn
Thr Ala Asn Gly
Thr Gly Ala Asn
Thr Gly Gly Lys
Thr Gly Gly Gln
Thr Gly Lys Gly
Thr Gly Asn Ala
Thr Gly Gln Gly
Thr Lys Gly Gly
Thr Asn Ala Gly
Thr Asn Gly Ala
Thr Gln Gly Gly
1-cyclopropyl-6-fluoro-8-hydroxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
C18H20FN3O4 (361.14377720000005)
Cinchonan-9-amine, 10,11-dihydro-6-methoxy-, trihydrochloride , (9R)
C20H28ClN3O (361.19207880000005)
Urea, N-[(2-chloro-6-methoxy-3-quinolinyl)methyl]-N-cyclopentyl-N,N-dimethyl- (9CI)
bis((r)-(-)-1-(1-naphthyl)ethyl)amine
C24H24ClN (361.15971740000003)
bis((s)-(+)-1-(1-naphthyl)ethyl)amine
C24H24ClN (361.15971740000003)
1-[(2-methylpropan-2-yl)oxycarbonyl]-4-oxospiro[3H-chromene-2,4-piperidine]-6-carboxylic acid
6-(4-(Ethoxycarbonyl)piperazin-1-yl)pyridine-3-boronic acid pinacol ester
C18H28BN3O4 (361.21727580000004)
1-CYCLOPROPYL-6-FLUORO-8-METHOXY-4-OXO-7-(PIPERAZIN-1-YL)-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID
C18H20FN3O4 (361.14377720000005)
3-(3-imidazo[1,2-b]pyridazin-2-ylphenyl)-5-(piperazin-1-ylmethyl)-1,2,4-oxadiazole
3,3-diphenyl-N-(3-phenylsulfanylpropyl)propan-1-amine
3-PHENYL-6-(3,4,5-TRIMETHOXY-PHENYL)-PYRAZOLO[1,5-A]PYRIMIDINE
N-([1,1-biphenyl]-4-yl)-9,9-dimethyl-9H-fluoren-2-amine
1-(4-Methylamino-2-piperidin-3-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-ethanone diHCl
C15H25Cl2N5O (361.14360600000003)
tert-Butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate
C19H28BNO5 (361.20604280000003)
2-[[4-[bis(2-hydroxyethyl)amino]phenyl]amino]-5-[(2-hydroxyethyl)amino]cyclohexa-2,5-diene-1,4-dione
C18H23N3O5 (361.16376280000003)
Semagacestat
D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
Methanone, [4-(5-chloro-2-methylphenyl)-1-piperazinyl][3-methyl-5-(1-methylethyl)-4-isoxazolyl]
2H-Pyrrol-2-one, 4-acetyl-1-(4-chloro-3-ethylphenyl)-5-cyclohexyl-1,5-dihydro-3-hydroxy-
C20H24ClNO3 (361.14446240000007)
1-TRIISOPROPYLSILANYL-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBOXYLIC ACID METHOXY-METHYL-AMIDE
N-[1,1-Biphenyl]-4-yl-9,9-dimethyl-9H-fluoren-3-amine
N-[1,1-Biphenyl]-2-yl-9,9-dimethyl-9H-fluoren-2-amine
Tert-Butyl(S)-1-((S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ylamino)-1-oxopropan-2-ylcarbamate
6-[2-(Dimethoxymethyl)-4-(6-methyl-2-pyridinyl)-1H-imidazol-5-yl] quinoxaline
2-(diethylamino)ethyl 2,2-diphenylpropanoate,hydrochloride
C21H28ClNO2 (361.18084580000004)
4-((4-(DIETHYLAMINO)PHENYL)IMINO)-N-METHYL-1-OXO-1,4-DIHYDRONAPHTHALENE-2-CARBOXAMIDE
1-Butanol, 4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]-
C23H27N3O (361.21540120000003)
5,7-dihydro-7,7-diMethyl-5-phenyl-indeno[2,1-b]carbazole
Dapiprazole Hydrochloride
C19H28ClN5 (361.20331180000005)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants Dapiprazole hydrochloride is a potent, selective and orally active alpha-1 adrenoceptor antagonist. Dapiprazole hydrochloride suppresses the opioid withdrawal symptoms. Dapiprazole hydrochloride is also used as eye drops for reversing mydriasis[1][2][3].
tert-butyl 4-[4-(trifluoromethoxy)phenoxy]piperidine-1-carboxylate
C17H22F3NO4 (361.15008480000006)
2-(1-(tert-Butoxycarbonyl)spiro[chroman-2,4-piperidine]-4-yl)acetic acid
C20H27NO5 (361.18891320000006)
buquinolate
C20H27NO5 (361.18891320000006)
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent
N-(Triphenylmethyl)-DL-serine Methyl Ester
C23H23NO3 (361.16778480000005)
Zimlovisertib
C18H20FN3O4 (361.14377720000005)
C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent > C184956 - IRAK4 Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C274 - Antineoplastic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Bradanicline
C78272 - Agent Affecting Nervous System Bradanicline is a highly selective α7 nicotinic acetylcholine receptor (nAChR) agonist (humanα7 nAChR: EC50=17 nM; Ki= 1.4 nM). Bradanicline is used for the research of cognitive disorders[1][2].
Prenoxdiazine
C23H27N3O (361.21540120000003)
R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent
1-[(2S)-2-(dimethylamino)-3-(4-hydroxyphenyl)propyl]-3-[(2S)-1-(thiophen-3-yl)propan-2-yl]urea
PZM21 is a potent and selective μ opioid receptor agonist with an EC50 of 1.8 nM[1][2][3].
Veliflapon
C23H23NO3 (361.16778480000005)
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors D002491 - Central Nervous System Agents > D000700 - Analgesics C78274 - Agent Affecting Cardiovascular System D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents
Etafenone hydrochloride
C21H28ClNO2 (361.18084580000004)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
2-[(4-phenyl-1-piperazinyl)methyl]-3,6-dihydro-2H-imidazo[1,2-c]quinazolin-5-one
4-[3-Methyl-5-(4-methylphenyl)-6-oxo-2,4-dihydropyrrolo[3,4-c]pyrazol-4-yl]benzoic acid methyl ester
N-(3,4-dimethoxyphenyl)-1-(3-methylphenyl)-4-pyrazolo[3,4-d]pyrimidinamine
8-Methyl-3-(2-propylpentanoyloxy)tropinium bromide
N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine
(2s)-3-[(R)-[(1s)-1-Amino-3-Phenylpropyl](Hydroxy)phosphoryl]-2-Benzylpropanoic Acid
C19H24NO4P (361.14428740000005)
D-Naphthyl-1-Acetamido Boronic Acid Alanine
C17H22BN2O6- (361.15708420000004)
L-Naphthyl-1-Acetamido Boronic Acid Alanine
C17H22BN2O6- (361.15708420000004)
5-(tert-butylsulfamoyl)-2-methyl-N-(5-methylpyridin-2-yl)benzamide
(2S)-3-(1H-indol-3-yl)-2-[[2-(1H-indol-3-yl)acetyl]amino]propanoic acid
(6R)-3,5,6-trihydroxy-2-(3-methylbutanoyl)-4,6-bis(3-methylbut-2-enyl)cyclo
(4R)-4,5-dihydroxy-2-(2-methylbutanoyl)-4,6-bis(3-methylbut-2-enyl)-3-oxocyclohexa-1,5-dien-1-olate
2-[4-[2-[[(2R)-2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]acetic acid
1-Amino-5-(4-morpholinyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinoline-2-carboxylic acid ethyl ester
1-(3,5-Dimethylphenyl)-3-[5-(dimethylsulfamoyl)-2-methylphenyl]urea
azanigerone D
An azaphilone that is the ester obtained by formal condensation of the carboxy group of 2,4-dimethylhexanoic acid with the tertiary hydroxy group of 7-hydroxy-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinoline-3-carboxylic acid.
N-[4-(dimethylamino)phenyl]-2-(1-oxo-[1,2,4]triazino[4,5-a]indol-2-yl)acetamide
4-[4-(2,3-dimethylphenyl)piperazine-1-carbonyl]-1H-quinolin-2-one
Ethyl 4-{[1-(ethylsulfonyl)piperidin-4-yl]carbonyl}piperazine-1-carboxylate
2-(2-methyl-1-benzimidazolyl)acetic acid [2-(2-methyl-1H-indol-3-yl)-2-oxoethyl] ester
3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)propanamide
1-[4-(2,3-Dimethylphenyl)-1-piperazinyl]-2-(1-methyl-3-indolyl)ethanone
C23H27N3O (361.21540120000003)
5-[4-(diethylamino)-2-methoxybenzylidene]-1-ethyl-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea
2-[methyl-(2,4,6-trimethylphenyl)sulfonylamino]-N-(2-pyridinylmethyl)acetamide
5-[[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-4-pyrazolylidene]methylamino]-1,3-dihydrobenzimidazol-2-one
2-cyclopropyl-N-[(1E)-1-(2,4-dihydroxyphenyl)ethylidene]quinoline-4-carbohydrazide
(3R)-3-{[(3R)-3-{[(3R)-3-{[(3R)-3-hydroxybutanoyl]oxy}butanoyl]oxy}butanoyl]oxy}butanoate
A hydroxy monocarboxylic acid anion resulting from the deprotonation of the carboxy group of (3R)-3-{[(3R)-3-{[(3R)-3-{[(3R)-3-hydroxybutanoyl]oxy}butanoyl]oxy}butanoyl]oxy}butanoic acid. A tetramer of (3R)-hydroxybutanoate; the major microspecies at pH 7.3.
2-[2-Hex-1-ynyl-6-(methylamino)-9-purinyl]-5-(hydroxymethyl)oxolane-3,4-diol
C17H23N5O4 (361.17499580000003)
2-(dimethylamino)-1-[(1S,5R)-7-[4-[(E)-2-phenylethenyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]ethanone
C23H27N3O (361.21540120000003)
(2S,3S,3aR,9bR)-1-(cyclopentylcarbamoyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid
C18H23N3O5 (361.16376280000003)
(2R,3R,3aS,9bS)-1-(cyclopentylcarbamoyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid
C18H23N3O5 (361.16376280000003)
2-[(1R,3R,4aR,9aS)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
2-[(1R,3R,4aS,9aR)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
2-[(1S,3R,4aR,9aS)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
N-[[(2R,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide
N-[[(2R,3S,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide
4-[(3aR,4S,9bS)-1-acetyl-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-8-yl]benzonitrile
2-[(1S,3S,4aS,9aR)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
2-[(1R,3S,4aR,9aS)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
2-[(1S,3R,4aS,9aR)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
2-[(1S,3S,4aR,9aS)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
2-[(1R,3S,4aS,9aR)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
[(2R,3S,4S)-1-(4-ethyl-2-thiazolyl)-4-[(2-methoxyethylamino)methyl]-3-phenyl-2-azetidinyl]methanol
N-[[(2R,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide
N-[[(2S,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide
N-[[(2R,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide
N-[[(2S,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide
4-[(3aS,4R,9bR)-1-acetyl-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-8-yl]benzonitrile
4-[(3aR,4R,9bS)-1-acetyl-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-8-yl]benzonitrile
4-[(3aS,4S,9bR)-1-acetyl-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-8-yl]benzonitrile
Butyl N-trifluoroacetyl 1-aminobutylphosphonate
C14H27F3NO4P (361.16297080000004)
4-(2-Butanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C17H31NO7 (361.21004159999995)
4-(3-Acetyloxy-2-pentanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C17H31NO7 (361.21004159999995)
carbocromen
C20H27NO5 (361.18891320000006)
C - Cardiovascular system > C01 - Cardiac therapy > C01D - Vasodilators used in cardiac diseases C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
H-Ile-Pro-Pro-OH (hydrochloride)
H-Ile-Pro-Pro-OH hydrochloride, a milk-derived peptide[1], inhibits angiotensin-converting enzyme (ACE)[1] with an IC50 of 5 μM[2]. Antihypertensive tripeptides[1].
SR59230A (hydrochloride)
C21H28ClNO2 (361.18084580000004)
SR59230A hydrochloride is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist[1] with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively[2].
(1s,2s,6r,8s,9s,10s)-9,15,16-trimethoxy-3-methyl-7,11-dioxa-3-azapentacyclo[8.8.0.0²,⁶.0⁶,⁸.0¹³,¹⁸]octadeca-13(18),14,16-trien-12-one
6-methoxy-13,16-dimethyl-19-(prop-1-en-2-yl)-15-oxa-4-azapentacyclo[14.3.1.0²,¹⁴.0³,¹¹.0⁵,¹⁰]icosa-2(14),3(11),5(10),6,8,12-hexaene
4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraene-13,16-diol
C20H27NO5 (361.18891320000006)
3-(acetyloxy)-1-[(10z)-8-methyl-2-oxa-6-azatricyclo[5.3.0.0¹,³]deca-6,8-dien-10-ylidene]butan-2-yl 2-methylbutanoate
C20H27NO5 (361.18891320000006)
(1r,4r,5r,13s,14s)-4-hydroxy-5,8-dimethoxy-13-methyl-6-oxa-13-azapentacyclo[8.6.2.1¹,⁵.0⁷,¹⁷.0¹⁴,¹⁸]nonadeca-7(17),8,10(18)-trien-13-ium-13-olate
C20H27NO5 (361.18891320000006)
7-carbomethoxyevodiamine
{"Ingredient_id": "HBIN013131","Ingredient_name": "7-carbomethoxyevodiamine","Alias": "NA","Ingredient_formula": "C21H19N3O3","Ingredient_Smile": "NA","Ingredient_weight": "361.39","OB_score": "NA","CAS_id": "69754-01-4","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7463","PubChem_id": "NA","DrugBank_id": "NA"}
1-(1s,7ar)-hexahydro-1h-pyrrolizin-1-ylmethyl 4-methyl (2r)-2-benzyl-2-hydroxybutanedioate
C20H27NO5 (361.18891320000006)
n-{5-[(2r,3s,4e,6z)-2,8-dihydroxy-7-[(1z)-prop-1-en-1-yl]octa-4,6-dien-3-yl]-4-hydroxy-2-methoxyphenyl}ethanimidic acid
C20H27NO5 (361.18891320000006)
(2r)-1-({4,7-dimethoxyfuro[2,3-b]quinolin-6-yl}oxy)-3-methoxy-3-methylbutan-2-ol
(1s,2s,5s,8s,9s,10s,11r,15s,18r)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-azapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadec-16-en-7-one
C20H27NO5 (361.18891320000006)
(1r,4r,5r,14s)-4-hydroxy-5,8-dimethoxy-13-methyl-6-oxa-13-azapentacyclo[8.6.2.1¹,⁵.0⁷,¹⁷.0¹⁴,¹⁸]nonadeca-7(17),8,10(18)-trien-13-ium-13-olate
C20H27NO5 (361.18891320000006)
9-methoxy-3,8-dimethyl-3-(4-methylpent-3-en-1-yl)-11h-pyrano[3,2-a]carbazole
(1s,13r,16s,17r)-17-hydroxy-9-methoxy-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9-trien-16-yl acetate
(1s,13r,16s,17r)-16-hydroxy-9-methoxy-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9-trien-17-yl acetate
9-methoxy-3,5-dimethyl-3-(4-methylpent-3-en-1-yl)-11h-pyrano[3,2-a]carbazole
3-(acetyloxy)-1-{8-methyl-2-oxa-6-azatricyclo[5.3.0.0¹,³]deca-6,8-dien-10-ylidene}butan-2-yl 2-methylbutanoate
C20H27NO5 (361.18891320000006)
n-{5-[(2z,4s,5e,7r)-1,7-dihydroxy-2-[(1z)-prop-1-en-1-yl]octa-2,5-dien-4-yl]-4-hydroxy-2-methoxyphenyl}ethanimidic acid
C20H27NO5 (361.18891320000006)
5-[({[(3r,3as,6ar,8s,9ar,9bs)-8-hydroxy-6,9-dimethylidene-2-oxo-octahydro-3h-azuleno[4,5-b]furan-3-yl]methyl}amino)methyl]oxolan-2-one
C20H27NO5 (361.18891320000006)
7-{[1-carboxy-2-(4-hydroxyphenyl)ethyl]-c-hydroxycarbonimidoyl}-3,5-dimethylhepta-4,6-dienoic acid
methyl 2-hydroxy-3-{4-[5-hydroxy-4-(2-methylpropyl)-2-oxopyrrol-3-yl]phenoxy}butanoate
(2s,3r)-3-(acetyloxy)-1-[(1s,3r,10z)-8-methyl-2-oxa-6-azatricyclo[5.3.0.0¹,³]deca-6,8-dien-10-ylidene]butan-2-yl (2s)-2-methylbutanoate
C20H27NO5 (361.18891320000006)
14-ethyl-9-oxo-8,16-diazahexacyclo[11.5.2.1¹,⁸.0²,⁷.0¹⁶,¹⁹.0¹²,²¹]henicosa-2,4,6,10,12(21)-pentaene-10-carboxamide
7-[(2,4-dimethylhexanoyl)oxy]-6-hydroxy-7-methyl-8-oxoisoquinoline-3-carboxylic acid
10-methoxy-3,5-dimethyl-3-(4-methylpent-3-en-1-yl)-11h-pyrano[3,2-a]carbazole
(2s)-1-({4,8-dimethoxyfuro[2,3-b]quinolin-7-yl}oxy)-3-methoxy-3-methylbutan-2-ol
17-hydroxy-9-methoxy-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9-trien-16-yl acetate
1-({4,7-dimethoxyfuro[2,3-b]quinolin-6-yl}oxy)-3-methoxy-3-methylbutan-2-ol
(4s,5r,6s,8s,10r)-10-[(2,6-dihydroxypyrimidin-4-yl)methyl]-5-methyl-2,11,12-triazatricyclo[6.3.1.0⁴,¹²]dodec-1-en-6-yl acetate
C17H23N5O4 (361.17499580000003)
(1r,2s,3s,5r,6r,8r,9s,11r,14s,16s,17s,18s,19r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,3,6,18,19-pentol
C20H27NO5 (361.18891320000006)
(3r)-10-methoxy-3,5-dimethyl-3-(4-methylpent-3-en-1-yl)-11h-pyrano[3,2-a]carbazole
3,8-dimethyl-3-(4-methylpent-3-en-1-yl)-11h-pyrano[3,2-a]carbazole-7,10-dione
C23H23NO3 (361.16778480000005)
(3r)-9-methoxy-3,5-dimethyl-3-(4-methylpent-3-en-1-yl)-11h-pyrano[3,2-a]carbazole
n-{5-[(2r,3r,4e,6z)-2,8-dihydroxy-7-[(1z)-prop-1-en-1-yl]octa-4,6-dien-3-yl]-4-hydroxy-2-methoxyphenyl}ethanimidic acid
C20H27NO5 (361.18891320000006)
9-hydroxy-2,2-dimethyl-10-(3-methylbut-2-en-1-yl)-11h-pyrano[2,3-a]carbazole-8-carbaldehyde
C23H23NO3 (361.16778480000005)
1-({4,8-dimethoxyfuro[2,3-b]quinolin-7-yl}oxy)-3-methoxy-3-methylbutan-2-ol
(1s,8s,10r,17s)-4,5,6,8-tetramethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraene
C20H27NO5 (361.18891320000006)
(3s)-3,8-dimethyl-3-(4-methylpent-3-en-1-yl)-11h-pyrano[3,2-a]carbazole-7,10-dione
C23H23NO3 (361.16778480000005)
(2s)-n-(5-carbamimidamido-1-oxopentan-2-yl)-2-[(1-hydroxypropylidene)amino]-3-phenylpropanimidic acid
10-methoxy-3,8-dimethyl-3-(4-methylpent-3-en-1-yl)-11h-pyrano[3,2-a]carbazole
(3s)-10-methoxy-3,8-dimethyl-3-(4-methylpent-3-en-1-yl)-11h-pyrano[3,2-a]carbazole
11-hydroxy-2,2-dimethyl-12-(3-methylbut-2-en-1-yl)-5h-1-oxa-5-azatetraphen-10-one
C23H23NO3 (361.16778480000005)
(1s,2s,6r,8s,9r,10s)-9,15,16-trimethoxy-3-methyl-7,11-dioxa-3-azapentacyclo[8.8.0.0²,⁶.0⁶,⁸.0¹³,¹⁸]octadeca-13(18),14,16-trien-12-one
5-hydroxy-2,2-dimethyl-12-(3-methylbut-2-en-1-yl)-11h-1-oxa-11-azatetracen-6-one
C23H23NO3 (361.16778480000005)
(1r,9s,10r,11r,12s)-13-[(2z)-3-methoxy-4-methyl-5-oxofuran-2-ylidene]-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-6-one
6-methoxy-8,16-dimethyl-19-(prop-1-en-2-yl)-15-oxa-4-azapentacyclo[14.3.1.0²,¹⁴.0³,¹¹.0⁵,¹⁰]icosa-2(14),3(11),5(10),6,8,12-hexaene
5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,3,6,18,19-pentol
C20H27NO5 (361.18891320000006)
9,15,16-trimethoxy-3-methyl-7,11-dioxa-3-azapentacyclo[8.8.0.0²,⁶.0⁶,⁸.0¹³,¹⁸]octadeca-13(18),14,16-trien-12-one
4,11,12-trimethoxy-17-methyl-17-azatetracyclo[8.4.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,11-tetraene-3,13-diol
C20H27NO5 (361.18891320000006)
(3s)-10-hydroxy-3-methyl-3-(4-methylpent-3-en-1-yl)-11h-pyrano[3,2-a]carbazole-8-carbaldehyde
C23H23NO3 (361.16778480000005)
(2s)-1-({4,7-dimethoxyfuro[2,3-b]quinolin-6-yl}oxy)-3-methoxy-3-methylbutan-2-ol
(2s,3s,9s,10s,12s)-12,20-dimethoxy-4-methyl-11,16,18-trioxa-4-azapentacyclo[11.7.0.0²,¹⁰.0³,⁷.0¹⁵,¹⁹]icosa-1(13),7,14,19-tetraen-9-ol
1-hexahydro-1h-pyrrolizin-1-ylmethyl 4-methyl 2-benzyl-2-hydroxybutanedioate
C20H27NO5 (361.18891320000006)
(3r,4e,6e)-7-{[1-carboxy-2-(4-hydroxyphenyl)ethyl]-c-hydroxycarbonimidoyl}-3,5-dimethylhepta-4,6-dienoic acid
n-{5-[(2z,4r,5e,7r)-1,7-dihydroxy-2-[(1z)-prop-1-en-1-yl]octa-2,5-dien-4-yl]-4-hydroxy-2-methoxyphenyl}ethanimidic acid
C20H27NO5 (361.18891320000006)
(1s,10s,13s)-4,11,12-trimethoxy-17-methyl-17-azatetracyclo[8.4.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,11-tetraene-3,13-diol
C20H27NO5 (361.18891320000006)